Synapsoft logo
AI Insights from Disclosures
Searching...
G2GBIO, Inc. 456160
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
G2GBIO, Inc. is a leading company in the field of long-acting drug microsphere technology, and it has next-generation microsphere source technology that meets the development needs of half-life extended drugs, as well as global-level mass production process facilities. Because the company's technology is a highly versatile platform technology capable of carrying drugs of various substances, including synthetic drugs, peptide drugs, antibody drugs, and RNA therapeutics, it has secured technology commercialization achievements, such as licensing and joint development with numerous global pharmaceutical companies in the market, and the company's technology also enables CDO / CDMO businesses.
Representative Director Lee Huiyong
Founded March 22, 2017
Corporation Type KOSDAQ
Industry Classification Manufacture of synthetic drug and other finished medicaments
Corporate number 16011-0451528
Business number 195-88-00664
Phone Number 043-270-6011
Fax Number 043-270-6099
Website None
Company Address 21 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant